Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20292764 | 0.92 | L3MBTL1 (0.53) | PTPN11PIK3CACKS1BSKP2L3MBTL1 | |
| SCHEMBL20292986 | 0.91 | PTPN11 (0.47) | PTPN11PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL20292924 | 0.86 | DYRK1A (0.54) | PTPN11ELANECKS1BSKP2L3MBTL1 | |
| SCHEMBL20304298 | 0.86 | PTPN11 (0.47) | PTPN11ELANECKS1BSKP2L3MBTL1 | |
| SCHEMBL20292770 | 0.86 | PTPN11 (0.51) | PTPN11PIK3CAELANECKS1BSKP2 | |
| SCHEMBL20292765 | 0.85 | CKS1B (0.47) | PTPN11ELANECKS1BSKP2L3MBTL1 | |
| SCHEMBL20293040 | 0.85 | PTPN11 (0.48) | PTPN11L3MBTL1ACVR1PTGDR2DYRK1B | |
| SCHEMBL20292779 | 0.83 | L3MBTL1 (0.53) | PTPN11L3MBTL1ACVR1PTGDR2SMN1; SMN2 | |
| SCHEMBL1781229 | 0.81 | L3MBTL1 (0.56) | ELANECKS1BSKP2L3MBTL1CYP11B1 | |
| SCHEMBL29283842 | 0.80 | PTPN11 (0.47) | PTPN11L3MBTL1GBA1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183786-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4183786-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3558321-B1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3558321-B1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | FELICITEX THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | FELICITEX THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3558321-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | Felicitex Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119039-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119039-A1 | DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | FELICITEX THERAPEUTICS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577365-B2 | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases | DYRK1A, DYRK1B, DYRK2 | PTPN11 474/4885PIK3CA 874/4885ELANE 4650/4885 |
| US-20180179199-A1 | DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES | DYRK1A, DYRK1B, DYRK2 | PTPN11 474/4885PIK3CA 874/4885ELANE 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.